Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inotiv, Inc.
  6. News
  7. Summary
    NOTV   US45783Q1004

INOTIV, INC.

(NOTV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inotiv : to Participate in the 2021 Colliers Institutional Investor Conference

08/31/2021 | 04:05pm EDT

WEST LAFAYETTE, Ind., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the 2021 Colliers Institutional Investor Conference, which will be held virtually, on Thursday, September 9, 2021.

About the Company

Inotiv, Inc. is a leading contract research organization specializing in nonclinical and analytical drug discovery and development services. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

Company ContactInvestor Relations
Inotiv, Inc.The Equity Group Inc.
Beth A. Taylor, Chief Financial OfficerKalle Ahl, CFA
(765) 497-8381(212) 836-9614
btaylor@inotivco.comkahl@equityny.com
  
 Devin Sullivan
 (212) 836-9608
 dsullivan@equityny.com


Primary Logo

Source: Inotiv, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about INOTIV, INC.
10/22INOTIV, INC. : Other Events (form 8-K)
AQ
10/04INOTIV : Announces Expansion of In Vivo Pharmacology Offering with Acquisition of Plato Bi..
PU
10/04INOTIV, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Finan..
AQ
10/04Inotiv, Inc. Enters into a Third Amendment to Amended and Restated Credit Agreement
CI
10/04INOTIV : Acquires Plato BioPharma for $15 Million
MT
10/04INOTIV : Announces Expansion of In Vivo Pharmacology Offering with Acquisition of Plato Bi..
AQ
10/04Inotiv, Inc. agreed to acquire Plato BioPharma, Inc. for $15 million.
CI
10/01INOTIV : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (fo..
AQ
10/01Inotiv, Inc. Enters into Second Amendment to Amended and Restated Credit Agreement with..
CI
09/28INOTIV : Financial Statements (unaudited) (Form 8-K)
PU
More news
Analyst Recommendations on INOTIV, INC.
More recommendations
Financials (USD)
Sales 2021 84,0 M - -
Net income 2021 -5,14 M - -
Net Debt 2021 - - -
P/E ratio 2021 -97,8x
Yield 2021 -
Capitalization 602 M 602 M -
Capi. / Sales 2021 7,17x
Capi. / Sales 2022 4,64x
Nbr of Employees 409
Free-Float 66,6%
Chart INOTIV, INC.
Duration : Period :
Inotiv, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOTIV, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 37,66 $
Average target price 64,50 $
Spread / Average Target 71,3%
EPS Revisions
Managers and Directors
Robert Leasure President, Chief Executive Officer & Director
Beth A. Taylor Chief Financial Officer, Secretary & VP-Finance
Gregory C. Davis Chairman
John Gregory Beattie Chief Operating Officer
Richard Allen Johnson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INOTIV, INC.0.00%602
MODERNA, INC.234.60%141 099
LONZA GROUP AG31.93%60 646
IQVIA HOLDINGS INC.43.58%49 145
SEAGEN INC.0.22%31 933
CELLTRION, INC.-39.69%25 328